Advancing Cancer Treatment with Brilliant Chemistry:
‍Learn About Zentalis' Clinical-Stage Oncology Therapies

Known cancer biology.
Deliberate medicinal chemistry.
Improving patient lives.

About Zentalis

Improving Patient lives

We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers.

Learn More

News

Read more

Pipeline

Compound
Indication
Trial Name + Development Approach
Phase 1
Phase 1b
Phase 2
Phase 3

Azenosertib WEE1 Inhibitor

Gynecologic malignancies
Other Tumor types
Platinum Sensitive Ovarian Cancer
1L maintenance setting
Phase 3
Platinum Resistant Ovarian Cancer
DENALI (ZN-c3-005)
Monotherapy
Phase 2
PARPi Resistant Ovarian Cancer
MAMMOTH (ZN-c3-006)
Azenosertib monotherapy, or with niraparib
Phase 2
Uterine Serous Carcinoma
TETON (ZN-c3-004)
Monotherapy, FDA Fast Track Designation
Phase 2
Solid Tumors
ZN-c3-001
Monotherapy
Phase 1b
Osteosarcoma
ZN-c3-003
Azenosertib + gemcitabine
Phase 1
BRAF Mutant Colorectal Cancer
ZN-c3-016
Azenosertib + encorafenib and cetuximab
Phase 1
Pancreatic Cancer
Azenosertib + gemcitabine
Phase 1
Breast Cancer
ZAP-IT
Azenosertib + carboplatin + pembrolizumab
Phase 1

ZN-d5 BCL-2 Inhibitor

Acute Myeloid Leukemia
ZN-d5-004C
ZN-d5 + azenosertib
Phase 1
Learn More

Join Zentalis

Be part of our vibrant team of dedicated professionals with the common goal of helping cancer patients and make a lasting impact.

Explore Careers